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Background: Type 2 Diabetes Mellitus (T2DM) poses a significant health and financial burden to in-
dividuals and healthcare systems. Omega-3 polyunsaturated fatty acids (PUFA) possess numerous
properties (e.g. anti-inflammatory, anti-thrombotic, anti-lipidemic) that may be beneficial in the man-
agement of T2DM and its complications.
Methods: In this narrative review, we discuss the potential mechanisms, clinical evidence-base, and
practical considerations regarding the use of omega-3 PUFA supplementation for the management of
glycaemic control and common comorbid conditions, including diabetic nephropathy and retinopathy,
liver disease, cognition and mental health, and cardiometabolic disease.
Results/conclusion: Omega-3 PUFA supplementation is generally well-tolerated and does not appear to
be contraindicated for patients on anticoagulant therapy; however, uncertainty persists regarding the
purity and stability of commercial omega-3 PUFA products. Despite promising animal studies, the current
clinical evidence for the use of omega-3 supplementation for the management of T2DM and associated
conditions is both limited and conflicting. Results from existing clinical trials do not support the use of
omega-3 PUFA for glycaemic control and there are limited studies in T2DM populations to support the
use of omega-3 PUFAs for associated complications of diabetes. Possible contributors to the conflicting
evidence base are study design issues, such as inadequate intervention period, sample size, omega 3
supplement dose, variations in the EPA to DHA ratio and clinical heterogeneity among diabetic
populations.
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Type 2 diabetes mellitus (T2DM) is a highly inflammatory and
pro-oxidant condition often resulting in comorbidities that affect
multiple body systems including large vessel diseases such as car-
diovascular disease, small vessel diseases such as retinopathy, ne-
phropathy, non-alcoholic fatty liver disease, and conditions that
affect cognitive performance and mental health [1e3].
Despite public health efforts to curb this pervasive chronic dis-
ease, it is currently estimated that over 414 million people world-
wide have T2DM and, by 2040, this number is projected to rise to
over 640 million [4]. T2DM has a high burden of disease; the direct
healthcare costs relating to T2DM in Australia are estimated at $1.7
billion per annum and indirect costs, including reduced produc-
tivity, absence fromwork and early retirement, are estimated at $14
billion per annum [5].
Consistent evidence from prospective cohort studies and large
primary prevention trials have demonstrated the protective bene-
fits of dietary patterns such as the Mediterranean diet, rich in anti-
inflammatory and antioxidant nutrients such as omega-3 fatty
acids, in prevention of T2DM and its complications [6e9].
Omega-3 polyunsaturated fatty acids (PUFA) include eicosa-
pentanoic acid (EPA, 20:5n-3) and docosahexanoic acid (DHA,
22:6n-3), derived primarily from fish and seafood, and alpha-
linoleic acid (ALA, 18:3n-3), from plant sources, such as leafy
greens, seeds, particularly flaxseed/linseed, and nuts, primarily
walnuts [10]. Long chain omega-3-PUFA modulate inflammatory
pathways by competing with the enzymatic metabolism of omega-
6 PUFA (arachidonic acid), which is converted to pro-inflammatory
eicosanoids such as prostaglandins, thromboxane, and leukotrienes
[11]. EPA is metabolised to the prostaglandins (PGE3), thrombox-
anes (TXA3), and leukotrienes (LTB5), which exert anti-
inflammatory and anti-coagulant effects [11]. In addition to anti-
inflammatory properties, omega-3 PUFAs possess several other
potentially beneficial properties, including anti-lipidemic, anti-
hypertensive, and anti-coagulant actions, and they have recently
been demonstrated to modulate gastrointestinal microbiota [12].
Furthermore, in animal studies, supplementation with omega-3
PUFA improved insulin sensitisation, potentially via increased
levels of adiponectin, an emerging protective risk factor, and
reduced inflammation [13,14].
The aim of this narrative review is to evaluate the efficacy of
omega-3 PUFA supplementation in the control of T2DM as well as
the amelioration of diabetic comorbidities such as diabetic reti-
nopathy and nephropathy, cardiovascular disease, cognitive and
mental health issues, and liver disease. Furthermore, practical
considerations regarding omega-3 PUFA supplementation
including adherence, symptoms, and potential adverse effects will
be discussed.
Relevant studies were primarily retrieved from PubMed and
Google Scholar search engines using search terms related to each
section of the review (e.g. diabetes, nephropathy) and omega-3PUFA (e.g. omega 3, EPA, DHA). A snowball strategy was also used
to retrieve relevant studies from the reference lists of included
studies. Due to the varied evidence-base for each condition dis-
cussed in this review, all study designs were eligible for inclusion
(e.g. clinical trials, observational, animal studies); however, when
extensive evidencewas available, RCTs were prioritised. Finally, due
to EPA and DHA, derived from fish oil, being the predominant long
chain omega-3 PUFAs within the literature, all reference to omega-
3 PUFA within this manuscript refers to fish oil-sourced EPA and
DHA unless otherwise stated.
2. Omega-3 PUFA supplementation and glycaemic control
Optimal glycaemic control is the cornerstone of diabetes man-
agement. Based on the findings of early epidemiological work
suggesting an inverse relationship between fish intake and glucose
intolerance [15], omega-3 PUFA supplementationwas postulated to
improve glycaemic control. Although the mechanisms involved are
still unclear [16], animal models have revealed the following po-
tential mechanisms: improved hepatic insulin sensitivity [17] via
hepatic fatty acid oxidation and reducing lipogenesis [18,19],
increased production of adipocytokines such as adiponectin and
leptin [20], direct [13] and indirect [21] anti-inflammatory effects
and associated improvements in insulin sensitivity in the liver,
muscle and adipose tissue, and modulation of incretin hormones,
which are involved in glucose-stimulated insulin secretion [22].
Despite the promising findings from animal studies, early hu-
man trials reported that omega-3 PUFA supplementation was
associated with deteriorated glycaemic control in T2DM patients
[23,24]. A recent meta-analysis of twenty RCTs with a total of 1209
T2DM patients reported that there were no significant differences
in markers of glycaemic control, including fasting blood glucose (19
of 20 studies included), postprandial plasma glucose (3 of 20
studies included), fasting insulin (17 of 20 studies included) and
HbA1c (10 of 20 studies included) with omega-3 PUFA supple-
mentation (0.52e3.89 g/day EPA and up to 3.69 g/day of DHA,
duration ranged 2e48 weeks) in comparison to control groups [25].
Subgroup analysis identified that duration of intervention (>8
weeks,8weeks), dose of EPA (<1.8 g/day,1.8 g/day), dose of DHA
(1.0 g/day, >1.0 g/day) and the ratio of EPA/DHA (EPA/DHA<1.4,
1.4 EPA/DHA1.5, EPA/DHA>1.5) were not associated with sta-
tistically significant differences in glycaemic control [25].
Conversely, fasting blood glucose was mildly increased in Asian
(weighted mean difference: 0.419mmol/L, 95% CI: 0.058 to
0.781mmol/L, p¼ 0.023) versus US/European populations [25].
However, a recent review exploring the impact of PUFA intake
(interventions included fish oil, nut oil, Portulaca oleracea L. seed
and a fish-based diet) on glycaemic control in T2DM populations,
concluded that PUFA supplementation of 0.42e5.2 g/day for at least
8 weeks may benefit glycaemic control, particularly in Asian pop-
ulations [26]. Geographical disparities in the effects of omega-3
PUFA supplementation have been previously reported, which may
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The findings of Chen and colleagues [25] are comparable to an
earlier Cochrane review of 23 randomised controlled trials with a
total of 1075 T2DM patients [28]. The dose of omega-3 PUFAs in the
included studies ranged from 1.08 to 5.2 g/day EPA and 0.3 to 4.8 g/
day DHA, with a mean total omega-3 PUFA dose of 3.5 g/d over a 2
week to 8-month duration. Omega-3 PUFA supplementation did
not significantly alter HbA1c (15 of 23 studies included), fasting
glucose (16 of 23 studies included) and fasting insulin levels (6 of 23
studies included). Dietary intake of omega-3 PUFAs was not
controlled for in the meta-analyses and measures of insulin resis-
tance were not included. The heterogeneous nature of diabetic
populations and variation in trial durations further hinders the
interpretation of findings. In addition, the discussed meta-analyses
reported on fasting insulin but the included studies did not use gold
standard measures of insulin sensitivity such as the
hyperinsulinemic-euglycemic clamp technique.
The effects of omega-3 PUFA supplementation on insulin
sensitivity in people with T2DM have also been summarised in a
recent review (EPA/DHA dose not specified in the review, duration
ranged 2 weekse6 months) [27]. The majority of RCTs discussed in
the paper reported no change in insulin sensitivity with omega-3
PUFA supplementation [27]. The remaining studies reported
inconsistent results, with omega-3 PUFA supplementation found to
both decrease [29] and improve [30] insulin sensitivity. Themethod
used to measure insulin sensitivity varied amongst studies and
further clarification regarding the effects of omega-3 PUFA sup-
plementation on measures of insulin sensitivity are required [27].
The effects of only docosapentaenoic acid (DPA, 22:5n-3), an
omega-3 PUFA found in red meat and some seafood, has not been
studied as extensively as combined DHA and EPA due to lower
levels of DPA in fish oil and a previous lack of concentrated DPA
products [31]. Recently, DPA supplementation was shown to be
effective in reducing blood glucose levels and improving homeo-
stasis model assessment of insulin resistance (HOMA-IR) in a ro-
dent model [32]. No human trials to our knowledge have
investigated the effects of pure DPA supplementation on the
management of T2DM and associated comorbidities, representing a
gap in current knowledge.
Based on the available evidence in human trials, omega-3 PUFA
supplementation to date appears to have a negligible effect on in-
sulin sensitivity and markers of glycaemic control including fasting
glucose, HbA1c, fasting insulin [28,33] and postprandial plasma
glucose. Further research is required to ascertain the effects of
omega-3 PUFA supplementation on glycaemic control in select
ethnic groups and using newer formulations.
3. Cardiovascular disease
Cardiovascular disease (CVD) is the most common cause of
morbidity andmortality in peoplewith T2DM [35]. In Australia, 65%
of all CVD deaths occur in people with T2DM or pre-diabetes [36].
Cardiovascular risk factors such as obesity, hypertension, dyslipi-
daemia, chronic low grade inflammation and oxidative stress are
common in patients with T2DM [35,37]. Insulin resistance also has
a direct biological effect on the vascular system, including micro- or
macro-angiopathy, reduced blood flow, peripheral arterial
dysfunction, as well as cardiomyocyte and endothelial cell
dysfunction [38]. Together, the high prevalence of cardiovascular
risk factors and the direct vascular complications in diabetes in-
crease the risk of coronary artery blockage, chronic heart failure
and stroke [37,38]. It is therefore important to consider whether
evidence supports a beneficial effect of omega-3 PUFA supple-
mentation on CVD risk factors and clinical end-points in the context
of T2DM.The most commonly analysed CVD risk factors regarding the
effect of omega-3 PUFA are plasma lipid levels. Three meta-
analyses have investigated lipid outcomes in studies of T2DM.
Themost recent of these studies included 20 RCTs which tested EPA
(0.52e3.89g) and DHA (0.48e3.69g) over 2e48 weeks duration
[25]. The second meta-analysis included 23 trials which tested EPA
(1.08e5.2g) and DHA (0.3e4.8g) over 2e8 months duration [28].
The final meta-analysis included 18 RCTs which tested EPA
(1.08e5.2g) and DHA (0.3e4.8g) over 3e24 weeks duration [33].
Each meta-analysis reported a significant mean reduction in tri-
glycerides levels ranging from 0.24mmol/L to 0.56mmol/L
compared to control groups [39e41]. The pooled effect of omega-3
PUFAs on low-density lipoprotein (LDL) and high-density lipopro-
tein (HDL) cholesterol levels was reported in two of these meta-
analyses [40,41]. Both demonstrated a significant mean increase
in LDL cholesterol, of 0.21mmol/L and 0.11mmol/L, respectively,
but had no effect on HDL levels. One meta-analysis did, however,
demonstrate a small but significant mean reduction in very low-
density lipoprotein (VLDL) levels of 0.07mmol/L compared to
control [41]. Interestingly, subgroup analyses in these latter two
meta-analyses highlighted different effects of omega-3 PUFA sup-
plementation when isolated to T2DM patients with hyper-
triglyceridemia. In one study, the triglyceride-lowering effect and
the elevation in LDL cholesterol were most marked in trials that
recruited hyper-triglyceridemic subjects [40]. In the other study, in
hyper-triglyceridemic patients alone, the increase in LDL was no
longer significant but the significant reduction in VLDL was seen in
these patients [41].
Whether omega-3 PUFAs can improve haemodynamic factors in
diabetes is important to consider as 60% of patients with T2DM
have high blood pressure [42]. A meta-analysis of five trials in
T2DM found that omega-3 supplementation (1.8e4g EPA, 1.2e4g
DHA, duration ranged 4e6 weeks) compared to placebo signifi-
cantly reduced diastolic blood pressure by a mean of 1.8mmHg
[43]; however, there was a non-significant reduction in systolic
blood pressure and heart rate (assessed in two trials). Amore recent
trial in women with T2DM demonstrated a significant mean
reduction in both systolic (5.4mmHg) and diastolic (1.2mmHg)
blood pressure with omega-3 PUFA supplementation (360mg EPA,
240mg DHA) when compared to placebo after 8 weeks [44]. It has
been proposed that the antagonist effects of omega-3 PUFA on
angiotensin II receptors are responsible for its beneficial effect on
elevated blood pressure [45].
Due to their effect on satiety, fat oxidation, and adipogenesis,
omega-3 PUFAs have also been investigated for their effect on
weight management [46]. However, a meta-analysis (previously
described with regards to lipids) reported omega-3 PUFA in-
terventions had no significant effect on body weight (9 trials
pooled) or BMI (4 trials pooled) when compared with control
groups in patients with T2DM [39]. These results did not differ
when subgroups for EPA/DHA dosage or study duration were ana-
lysed. One included study, conducted in women only, reported that
omega-3 PUFA (1.08 g EPA, 0.72g DHA) supplementation had no
effect on body weight but significantly reduced total fat mass and
subcutaneous adipocyte diameter compared to placebo after 2-
months [47].
One of the clear pathophysiological links betweenT2DM and the
development of CVD is the defective production of nitric oxide and
concomitant rise in oxidative stress [48]. However, studies inves-
tigating omega-3 PUFA interventions and markers of oxidative
stress in humans are sparse [49]. One study has specifically inves-
tigated the effect of omega-3 PUFAs (1.8 g EPA, 1.5 g DHA) on redox
balance in T2DM in vivo [50]. After 8-weeks, omega-3 PUFA sup-
plementation reduced 8-isoprostane and superoxide levels in
platelets from patients with T2DM and hypertension, but not in
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production.
Other risk factors which have been investigated in omega-3
PUFA interventions of T2DM are markers of vascular function. A
meta-analysis of 10 trials, conducted in both humans and animals,
concluded that omega-3 PUFA supplementation significantly
improved arterial stiffness, and this effect was despite no signifi-
cant changes in blood pressure [51]. The authors proposed that
reduced arterial stiffness related to changes in functional mecha-
nisms such as changes in aortic blood pressure and wave re-
flections, which are distinct from brachial blood pressure. Two of
the reviewed trials were specifically conducted in patients with
T2DM. One study found that purified EPA (1.8 g) improved pulse
wave velocity in large elastic (carotid) arteries after 2-years [52]
and the other demonstrated improved arterial compliance, but no
effect on stroke volume or systemic vascular resistance with 6-
weeks fish oil supplementation (1.8 g EPA, 1.2 g DHA) [53]. Endo-
thelial dysfunction is recognised as a major mediator of vascular
disease associated with diabetes [54]. A recent paper reviewed the
ability of omega-3 PUFAs to improve endothelial dysfunction in
individuals with classic risk factors for atherosclerosis [55]. They
concluded that omega-3 PUFAs improved endothelial dysfunction
(as measured using flow mediated dilation, forearm blood flow, or
peripheral arterial tonometry) in 16 of 17 trials in individuals with
hyperlipidaemia, metabolic syndrome, elevated BMI, or that
smoked, but only in 2 of 5 studies of patients with T2DM. The 5
studies in T2DM patients each tested effects of EPA and DHA (total
1e4g), except one which tested EPA (3.8g) versus DHA (3.7g), and
their duration ranged between 4 and 12 weeks.
The evidence for prevention of clinical CVD with omega-3
supplementation has recently been summarised in a review from
the American Heart Association (AHA) [56]. The reviewwas limited
to RCTs of supplementation with major clinical CVD end-points.
Their review located only one RCT that was designed to test the
effects of omega-3 PUFA supplements on CVD end-points in pa-
tients with T2DM: the ORIGIN (Outcome Reduction With Initial
Glargine Intervention) trial [57] which randomly assigned patients
who were at high risk for cardiovascular events and had pre-
diabetes or T2DM to receive 1 g of ethyl esters of omega-3
(465mg EPA, 375mg DHA) PUFAs (n¼ 6281) or placebo
(n¼ 6255) daily and to receive either insulin glargine or standard
care. After 6-years follow up they found no difference in incidence
of CVD deaths or major vascular events between the omega-3 PUFA
supplementation and placebo groups. There is currently an ongoing
RCT in the United Kingdom, ASCEND (A Study of Cardiovascular
Events in Diabetes), that seeks to examine the effects of omega-3
PUFA supplements (1g ethyl esters, 0.41g EPA, 0.34g DHA daily)
on cardiovascular events among patients with T2DM that are free of
prior clinical CVD [58].
Other RCTs investigating the effect of omega-3 PUFA supple-
mentation on CVD end-points have performed sub-group analyses
in patients with T2DM. One study found that in recent myocardial
infarction (MI) patients with T2DM there was no difference in
sudden cardiac death within 3-weeks of hospital stay between
groups randomised to omega-3 PUFA (460mg EPA, 380mg DHA) or
placebo [59]. Conversely, in Japanese subjects with hypercholes-
terolemia and impaired glucose metabolism supplementation with
highly purified EPA (300mg) significantly reduced coronary artery
disease incidence by 22% at 4.6 years follow-up [60]. Another study,
in a sub-group of patients post- MI with T2DM, found that com-
bined EPA (223mg), DHA (149mg) and ALA (1.9g) supplementation
resulted in lower incidence of combined ventricular arrhythmia-
related events and fatal MI compared to placebo after 4-years [61].
Despite the substantial body of evidence that has investigated
omega-3 PUFA supplementation on CVD risk factors within T2DMpopulations, the effect of omega-3 PUFAs on clinical CVD endpoints
(e.g. mortality, CVD events) is currently unclear. Omega 3 PUFA
supplementation is therefore not recommended by the AHA for the
prevention of CVD in patients with T2DM [56]. However, for the
secondary prevention of CVD in the general population, the AHA
considers omega-3 PUFA supplementation reasonable [56]. In
Australia, The National Heart Foundation recommend combined
EPA and DHA 1g/day through 2e3 serves of oily fish per week,
supplements or enriched food/drinks, and ALA >2g per day through
foods for secondary prevention of CVD [62].
4. Non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is the most common
liver disease globally, affecting approximately 30% of the popula-
tion [63]. NAFLD is a progressive disease that encompasses a
spectrum of conditions ranging from simple steatosis, non-
alcoholic steatohepatitis (NASH) and finally cirrhosis [64]. As the
condition progresses, there is an increase in hepatic steatosis,
fibrosis, and inflammation. NAFLD is frequently referred to as the
hepatic manifestation of the metabolic syndrome and pre-diabetes,
as they often coexist with several other cardio-metabolic risk fac-
tors [65]. The pathophysiological mechanism which underpins
NAFLD is insulin resistance and it is therefore, strongly associated
with the onset and presence of T2DM [65]. Increased concentra-
tions of blood glucose specifically stimulate hepatic lipogenesis,
promoting liver lipid accumulation leading to higher incidence of
NAFLD [66]. Thus, NAFLD is present in 70e90% of patients with
T2DM and has been recognised as an independent risk factor for
cardiovascular disease in this patient group [64,67,68]. In addition,
NAFLD is an independent risk factor for the development of T2DM
[69] and T2DM increases the risk of NAFLD patients further
developing cirrhosis or hepatocellular carcinoma [70].
Omega-3 PUFAs lower hepatic lipids and attenuate inflamma-
tion [71,72]. These beneficial effects are mediated through the
regulation of hepatic lipid metabolism, adipose tissue function and
through interfering with the arachidonic acid pathway of inflam-
mation, reducing hepatic triglyceride (TG) accumulation [73].
Within hepatocytes, omega-3 PUFAs downregulate gene expres-
sion of several genes involved in lipogenesis by inhibiting SREBP-1c
and upregulate lipid oxidation by activating PPARawhich facilitates
fatty acid transfer into the mitochondria [74,75]. EPA and DHA have
been shown to regulate a number of transcription factors that
control critical components of hepatic fatty acid metabolism
[76,77]. This includes attenuating the expression of transcripts
linked to fibrosis such as collagen subtypes, extracellular matrix
remodelling, tissue inhibitors of metalloproteases, matrix metal-
loproteases, and lysyl oxidases [72].
The effect of omega-3 PUFA treatment in NAFLD has recently
been summarised in four meta-analyses of RCT's [78e81]. These
meta-analyses assessed between three and nine clinical trials each
with up to 591 patients. The median dose of omega-3 PUFA ranged
from 0.83 to 9.0 g/day and the treatment duration ranged from 2 to
18 months. The distribution of EPA and DHAwas variable, with EPA
ranging from 35-60%, DHA from 23.9-250% and three studies did
not specify composition of EPA and DHA. The results indicated that
omega-3 PUFA treatment may improve markers of hepatic damage,
most of these parameters measured were plasma markers of liver
function (e.g. ALT, AST and/or GGT). For ultrasound-proven assess-
ment of liver fat, a meta-analysis that included five studies was
conducted. There was significant heterogeneity observed between
studies. Results indicated a significant pooled omega-3 PUFA
therapy was effective for liver fat (OR¼ 3.60, 95% CI: 1.31 to 9.89,
??¼ 0.01) [79]. It is of note, however, that limited NASH specific
markers were assessed and thus, improvement in liver integrity can
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Only one small (N¼ 37), albeit double-blind randomized
placebo-controlled clinical trial was identified by these reviews
that was conducted in NAFLD participants specifically with T2DM.
This study reported no improvement in measures of NASH histol-
ogy with the treatment of omega-3 PUFA supplementation (2.16g
EPA, 1.44g DHA) compared to placebo [82].
The existing clinical research that has investigated the effect of
omega-3 PUFAs in patients with NAFLD and T2DM is limited by
variability in omega-3 PUFA dosage and differing EPA to DHA ratios.
Due to the range of dosages used in the current body of literature,
the relative superiority of either EPA and/or DHA to improve health
outcomes in patients with NAFLD is unclear. Furthermore, in par-
ticipants with NAFLD, it is also important to quantify the effect of
omega-3 PUFA supplementation on hepatic steatosis and/or
fibrosis to determine the direct impact on liver specific outcomes.
5. Diabetic nephropathy and kidney-related complications
Diabetic nephropathy is a common consequence of both dia-
betes and chronic kidney disease (CKD). Diet is an important
modifiable risk factor in CKD [83] and diabetic nephropathy [84].
While renal guidelines have many isolated nutrient targets, dietary
fat targets are not common features in renal best practice guide-
lines [85,86]. This comes despite the fact that dietary fat intake is
approximately 40% of total energy intake in renal populations, with
the majority of that being from saturated fat [87e90]. The issue
with this being that a diet high in saturated fat was shown to be
associated with higher incidence of albuminuria [91], which is a
common complication of diabetic nephropathy and important risk
factor for kidney disease progression.
Dietary omega-3 PUFAs have gained an interest in CKD for their
anti-inflammatory properties, and potentially beneficial effects on
blood pressure, endothelial function, and proteinurea [92,93]. In
the general population (free from CKD), omega-3 PUFA intake
(0$31e4$18g daily) has been shown to correlate with lower inci-
dence of CKD [94]. For people with T2DM, the European Prospec-
tive Investigation of Cancer (EPIC) study showed that consuming at
least two servings of fish per week lowered their risk of macro-
albuminuria [95]. Interestingly, this associationwas independent of
omega-3 PUFA content of the fish consumed, where higher intake
of fish both high and low in omega-3 PUFAs was inversely associ-
ated with macroalbuminuria [95]. However, this study did not
quantify omega-3 PUFAs in their analysis, making conclusions on
omega-3 PUFAs less reliable. In the CKD population specifically, a
12-week intervention study showed omega-3 PUFA supplementa-
tion (3.6 g daily) to reduce triglyceride levels, retard CKD progres-
sion, and having the capacity to reduce inflammation and oxidative
stress [96].
Studies in diabetic nephropathy specifically are limited. Early
rodent models suggest a higher omega-3 PUFAs intake, particularly
omega-3 PUFAs (from fish oil), to reduce albuminuria in diabetic
nephropathy [93] In human trials, however, the effects are far from
conclusive, likely owing to the short durations and small sample
sizes of current studies [97]. An early study in patients with T2DM
did not find any benefit for 12 month omega-3 PUFA (4.6g/day)
supplementation and albuminuria, kidney function, blood pres-
sure, and dyslipidaemia [98]. Another similar trial supports this
finding, however, when the analysis was restricted to people with
diabetes who were taking renineangiotensin system blocking
medication, albuminuria was significantly lower in the omega-3
PUFA intervention arm (4g/day; duration 6 weeks) compared to
the placebo [99].
Notwithstanding the inconsistencies in the evidence to date, a
multitude of studies have shown reductions in proteinuria/albuminuria following omega-3 PUFA (0.85g EPA, 0.58g DHA per
day; duration 4 years) supplementations in CKD complications
[100,101]. For example, meta-analysis of trials in patients with
diabetic nephropathy, lupus, or IgA nephropathy have suggested a
greater reduction in urine protein excretion (UPE) after omega-3
PUFA supplementation (dose range for EPA and/or DHA: 0.7 to
5.1g/day; median follow-up 9 months) [102]. These conclusions
became less reliable, however, when the analysis was restricted to
studies involving only participants with diabetes, who showed no
significant reduction in UPE [103].
Currently, omega-3 PUFA supplementation should not be
advocated for preventing kidney complications in diabetic ne-
phropathy [93]. The existing literature is limited by insufficient
study power, clinical heterogeneity among diabetic and CKD pop-
ulations, and comparing microalbuminuria with macro-
albuminuria. Well designed and adequately powered effectiveness
trials are needed to confirm the hypothesis that omega-3 PUFA
supplementations is an effective strategy to combat kidney com-
plications in diabetic nephropathy.
6. Diabetic retinopathy
Diabetic retinopathy is the most common microvascular and
ocular complication of diabetes and is a leading and increasing
cause of preventable vision loss and blindness in the working-age
population [104]. A growing body of evidence suggests omega-3
long-chain polyunsaturated fatty acids may have a role not only
in retinal health, but also in some retinal diseases [105], including
diabetic retinopathy.
In the earliest animal study, the adverse effects of omega-3
PUFAs in rats with diabetes induced by streptozotocin, a com-
pound toxic to pancreatic beta cells, were observed, including
increased formation of occluded retinal capillaries and no reduc-
tion in pericyte loss [106]. By contrast, another study reported that
increasing levels of omega-3 PUFAs or their bioactive metabolites
reduced pathological angiogenesis (i.e. proliferative diabetic reti-
nopathy) in mice with diabetes [107]. Since Western diets often
contain sub-optimal levels of omega-3 PUFAs, supplementation
was flagged as potentially beneficial in preventing diabetic reti-
nopathy [107]. A subsequent study found a diet balanced in long-
chain PUFAs modified retinal lipid membranes in diabetic rats
and prevented rod photoreceptor dysfunction [108]. Soon after, 5-
Lipoxygenase metabolite 4-HDHA was identified as the mediator
of the anti-angiogenic effect of omega-3 PUFA in a mouse model of
proliferative diabetic retinopathy [109]. The same research group
expanded their animal proliferative diabetic retinopathy research
to include retinal function in a mouse model of T2DM and reported
beneficial effects of dietary omega-3 PUFAs and adverse effects of
omega-6 PUFAs on visual function in T2DM. These results suggest
dyslipidaemia in diabetes may negatively impact vision [110].
Diabetic rats supplemented with a range of nutrients, including
omega-3 PUFAs, for 4 months prevented increased cell apoptosis in
capillaries and other vascular pathology, and attenuated diabetes-
induced features of diabetic retinopathy [111].
Although omega-3 PUFAs have a beneficial effect in animal
models of diabetic retinopathy, the clinical relevance of omega-3
PUFAs in human retinopathies is unclear, possibly due to the
paucity of human studies in this area. Another reason for uncer-
tainty may be that circulating lipid levels need to be interpreted
carefully since they may be dependent on fasting status and
medication use, particularly statins, independent of retinal disease
or diabetes status [112]. The first review of effects of omega-3 fatty
acids on eye health in humans noted that, in a poorly-reported
small study of 48 individuals with diabetes supplemented with
4g omega-3 fatty acids for 3 months, small improvements in some
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tioning retinal capillaries within 1mm of the ‘field of vision’, were
observed [113].
In contrast, in a well-conducted prospective observational study
in Spain [114], older patients with T2DM who consumed a back-
groundMediterranean diet and had a dietary omega-3 PUFA intake
equivalent to at least two weekly servings of oily fish had a
significantly lower risk of sight-threatening diabetic retinopathy
than those who ate less than the recommended amount. To
determine the effect of baseline intake of different fats on the risk of
3614 people, ages 55e80, with T2DM were enrolled in the Pre-
vencion con Dieta Mediterranea (PREDIMED) study, which
compared Mediterranean diets supplemented with either extra-
virgin olive oil or nuts with a low-fat control diet. According to
completed food questionnaires, 75% of participants adhered to the
recommendation of at least 500mg per day of omega-3 PUFAs i.e.
two servings of fatty fish weekly. At six-year follow-up, those with
adequate omega-3 PUFA intake at baseline had a 48% lower risk of
developing diabetic retinopathy compared to those with inade-
quate intakes. However, researchers cautioned supplements would
not necessarily yield the same benefits as dietary omega-3 PUFA as
all factors influencing diabetic retinopathy in participants had not
been accounted for. Clearly, more human studies of the effects of
diet and omega-3 PUFAs on diabetic retinopathy in different pop-
ulations consuming a range of background diets are warranted.
7. Mental health and cognition
Diabetes, cognitive problems, and mental disorders are
frequently comorbid, and epidemiological evidence has demon-
strated that individuals with glucose intolerance, obesity, and
T2DM are at increased risk for brain disorders such as cognitive
problems, dementia or depression [115e117]. Poor quality diets,
such as Western style diets high in processed foods, added sugar
and saturated fat have been associated with metabolic disease and
obesity, which in turn are known risk factors for poor cognition and
mental health [118e120]. While the underlying biological factors of
this association are not completely understood, there are various
neurological and peripheral mechanisms that are hypothesized in
this relationship. As the primary energy source for the brain,
glucose homeostasis and associated insulin signalling are impor-
tant to neural health and function [121]. The poor glucose meta-
bolism and impaired insulin signalling that is typical of T2DM may
be associated with disrupted central nervous system function and
as well as atrophy of the hippocampus and neurodegeneration
[122,123]. Additionally, poor regulation of blood glucose in T2DM
may initiate acute changes in cerebral blood flow, microvascular
changes, and dysregulation of the HPA axis and subsequently, in-
crease hippocampal exposure to glucocorticoids [124]. Further,
hyperglycaemia and insulin resistance have been linked with
inflammation and oxidative stress, both of which have been iden-
tified as risk factors and potential mechanisms associated with
mood disorders [125,126].
Omega-3 PUFAs are understood to have neuroprotective effects,
and to promote healthy brain function, cognition, and mood
[127e129]. Omega-3 PUFA supplementation has been associated
with reductions in inflammation and oxidative stress [130e133].
Given that overweight/obesity and glucose intolerance are under-
stood to contribute to inflammation, omega-3 PUFA supplemen-
tationmay counteract peripheral inflammation and oxidative stress
associated with T2DM [134], and may also act as a protective buffer
against inflammation and dysregulated insulin activity, both
peripherally and in the brain [135,136]. Further, meta-analyses of
RCTs suggest that omega-3 PUFA supplementation, particularly
formulations with a high EPA to DHA ratio, may be protectiveagainst cognitive decline and risk of mood disorders [137e140].
While the effects of omega-3 PUFA supplementation on cognitive
function and mental health have not been well studied specifically
among populations with T2DM, the broader literature supporting
the neuroprotective and anti-inflammatory benefits of omega-3
PUFA supplementation suggests that this may be a beneficial
strategy among people with T2DM [141,142]. However, recent
literature has highlighted that individual characteristics, such as
high or low baseline inflammation (as measured by interleukin-1ra,
c-reactive protein, and adiponectin), may predict treatment
response to omega-3 PUFAs and thus should be considered among
this population [143]. Omega-3 PUFA supplementation, in combi-
nation with lifestyle modification (i.e. weight loss, reduction of
saturated fat intake) may offer a low-risk neuroprotective strategy
in T2DM, and this area warrants further investigation. While sup-
plementation may not modulate glucose metabolism or insulin
function directly, it may reduce the likelihood of comorbid psy-
chiatric or neurodegenerative conditions that may complicate
diabetes treatment or prognosis [144,145].
8. Practical considerations of omega-3 PUFA
supplementation
To inform clinical use of omega-3 PUFA supplementation in the
diabetic population, relevant practical issues need to be considered.
These include patient's attitudes towards supplementation, the
possibility of adverse events, issues related to supplement purity,
dose, and cost of obtaining omega-3 PUFAs via supplementation
versus food.
There is limited data on the use of omega-3 PUFA supplemen-
tation amongst populations with diabetes. The overall reported use
of complementary and alternative medicine in diabetic populations
ranges from 17% to 73% [146], which is comparable to usage rates in
the general population [147,148]. In the Freemantle Diabetes Study
[147], up to 14% of patients with T2DM indicated that they had
previously taken fish oil/omega 3 supplementation. Manya et al.
[149] explored diabetic patients reasons for taking supplementa-
tion and found that only 3% of subjects currently using fish oil were
doing so ‘specifically to treat diabetes’. These results suggest that
while people living with T2DM do not commonly use omega-3
PUFA supplements, they are open to supplement use in general.
Due to the increased risk of CVD associated with T2DM, patients
with diabetes are frequently prescribed anti-coagulant medications
such as aspirin. It has been postulated that omega-3 PUFA sup-
plements and anticoagulant, and antihypertensive drugs are con-
traindicated [150]. Theoretically, bleeding could occur due to the
anti-thrombotic properties of EPA and DHA [151]. However, a re-
view [151] examining the safety of omega-3 PUFA supplements
(0.03e1.86g EPA, 0.15e1.72 g DHA per day, taken for 6 to 52 weeks)
failed to identify any severe adverse events (bleeding, death,
bruising) that were likely to be attributable to omega-3 PUFA use. A
related review on safety considerations with omega-3 fatty acid
therapy, concluded that there is little evidence that either ‘low-
edose’ (<1g/day) or ‘high-dose’ (typically 5e6g/day) omega-3
supplementation increase bleeding risks in patients being treated
with antiplatelet or anticoagulant therapies [152]. Likewise, an RCT
assessing fish oil supplementation (32% EPA; 23% DHA; dose 2.7g/
day or 6.1g/day) in high-risk pregnancies found no evidence of
increased risk of adverse events when the prophylactic (2.7g/day)
and therapeutic (6.1g/day) trial arms were compared to an olive oil
control group [153]. While the existing evidence does not support
any clinically significant risks of bleeding with use of omega-3
PUFAs at standard doses, individuals with bleeding disorders may
require additional monitoring and supervision [154]. Congenital
bleeding disorders occur in approximately 1% of the population and
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Individuals commonly report gastrointestinal (GI) symptoms
(especially eructation) with fish oil use. Five of the 17 studies in the
review by Villani et al. [151] reported on GI symptoms. The prev-
alence of GI symptoms ranged from 3 e 53.8%; occurrence of GI
symptoms did not appear to be affected by supplement dose or
composition. The authors concluded that there is unlikely to be
differences in GI disturbances between omega-3 PUFAs and pla-
cebo supplements (e.g. sunflower oil) [151].
Additional concerns specific to omega 3 PUFA supplementation
relate to the stability and purity of commercial supplement prod-
ucts. Due to their long chain chemical structure, omega-3 PUFAs are
prone to oxidation if exposed to excess heat and/or light. Improper
storage of commercial omega-3 PUFA supplements may result in
oxidised products and negate the potential beneficial health effects
of supplementation. Two recent analyses of several commercial fish
oil products have provided conflicting results with one analysis
finding few products met recommendations of oxidation markers
while the other study finding the opposite [156,157]. Possible rea-
sons for this conflict are due to the type of analysis and range of
supplements tested. Furthermore, due to the bioaccumulation of
heavy metals and organic pollutants in animal lipid reserves, ma-
rine sources of omega-3 PUFAs (e.g. fish oils) may contain signifi-
cant levels of these compounds [158]. Previous studies that have
investigated the content of various pollutants in marine omega-3
PUFAs have identified some products that exceeded recom-
mended intakes of pollutants but most products were below the
recommended levels [158,159].
The common therapeutic dosages for omega-3 range from 1-4g/
day [160]. For reference, two grams of omega-3 fatty acids can be
obtained by eating around 100 g of Atlantic salmon [161] or taking 2
to 10 fish oil capsules. For many individuals, these amounts are
difficult to achieve with food alone. While omega-3 supplements
range in price, and fish oil supplements with higher concentrations
of EPA and DHA tend to me more expensive [162,163], economic
analyses have demonstrated that, per mg, omega-3 PUFA supple-
ments are always cheaper than food sources of omega-3 [162,163].
Accordingly, supplements represent a viable and practical means of
obtaining adequate omega-3 PUFAs. However, in the context of
whole of diet patterns (such as the Dietary Approaches to Stop
Hypertension [DASH] diet and the Mediterranean diet), dietary
sources of omega-3 PUFAs such as fish and flax seeds also contain a
wide range of compounds including taurine, polyphenols, sele-
nium, and fibre that may provide unique health benefits. Further-
more, in contrast to the use of omega-3 PUFA supplements,
consumption of a wholefood item rich in omega-3 PUFAs (e.g. fish)
will improve overall diet quality by displacing a potentially low-
nutrient density food item [164]. Therefore, whole food sources
of omega-3 PUFAs should be encouraged and evidence-based
omega-3 supplementation should be seen as an adjunct to, rather
than replacement for food.
9. Future directions and conclusion
Despite promising animal studies, the current clinical evidence
for the use of omega-3 supplementation for the management of
T2DM and associated conditions is both limited and conflicting.
Currently, the clinical evidence does not support the use of omega-
3 PUFA supplementation for improving glycaemic control and there
is insufficient evidence to make recommendations on the use of
omega-3 PUFAs for diabetic nephropathy and retinopathy. While
there is promising evidence for the use of omega-3 supplementa-
tion for NAFLD-related outcomes and mental health from non-
diabetic populations, there is limited clinical evidence in diabetic
populations to support its use. As discussed in detail in our recentlypublished review on the controversies in omega-3 PUFA supple-
mentation trials [160], possible explanations for the conflicting
evidence base are issues with study design such as inadequate
intervention periods and sample size of studies, inadequate dose of
supplements, variations in the ratio of EPA to DHA and clinical
heterogeneity among diabetic populations (e.g. evaluating diabetic
nephropathy in patients with microalbuminuria and macro-
albuminuria). Meta-analyses of RCTs suggest that omega-3 PUFAs
are effective in reducing triglycerides in T2DM. However, there is
insufficient evidence to support the use of omega-3 PUFAs for other
CVD risk factors (e.g. oxidative stress) and clinical endpoints in the
T2DM context. Although omega-3 supplementation appears to be
generally well-tolerated, clinicians should consider issues
regarding possible contraindications as well as oxidation and im-
purity issues with some commercial products. Finally, omega-3
PUFA supplements are a cost-effective method of achieving thera-
peutic doses. However, due to the beneficial effect of dietary
sources of omega-3 PUFAs in improving diet quality and improving
intake of other beneficial nutrients, food sources of omega-3 PUFAs
should be prioritised.
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